Reducing the Excess Activin Signaling Rescues Muscle Degeneration in Myotonic Dystrophy Type 2 Drosophila Model.

Area of Science:

• Genetics
• Molecular Biology
• Pharmacology

Background:

• Myotonic dystrophy type 2 (DM2) is caused by expanded CCUG non-coding RNA repeats.
• Effective treatments and drug targets are urgently needed to slow DM2 progression.

Purpose of the Study:

• To identify potential therapeutic strategies for DM2 by screening FDA-approved small-molecule drugs.
• To investigate the role of the TGF-β pathway, specifically activin signaling, in DM2 pathogenesis.

Main Methods:

• A DM2 Drosophila model expressing 720 CCTG repeats in muscle was utilized.
• 3140 FDA-approved small-molecule drugs were screened for effects on lethality and locomotion phenotypes.
• Activin signaling levels (p-smad3) and muscle pathology were assessed in DM2 flies.

Main Results:

• Ten drugs were identified that significantly improved survival and locomotor activity in DM2 flies.
• Four of the identified drugs target components within the TGF-β pathway.
• Reduced activin signaling, through inhibitors or genetic methods, ameliorated muscle degeneration and climbing defects in DM2 flies.

Conclusions:

• Decreased activin signaling is sufficient to rescue DM2-associated muscle degeneration.
• Activin signaling represents a promising therapeutic target for treating myotonic dystrophy type 2.